Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.63 |
| ▸ | MAP2K2 | P36507 | 5/20 | 0.38 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.35 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL696775 | 0.92 | MAP2K1 (0.61) | MAP2K1MAP2K2 | |
| SCHEMBL2426514 | 0.90 | MAP2K1 (0.71) | MAP2K1MAP2K2 | |
| SCHEMBL697714 | 0.90 | MAP2K1 (0.51) | MAP2K1 | |
| SCHEMBL696723 | 0.82 | MAP2K1 (0.49) | MAP2K1 | |
| SCHEMBL13148451 | 0.82 | MAP2K1 (0.73) | MAP2K1MAP2K2 | |
| SCHEMBL4348377 | 0.82 | MAP2K1 (0.65) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL696855 | 0.81 | MAP2K1 (0.70) | MAP2K1MAP2K2 | |
| SCHEMBL13147940 | 0.79 | MAP2K1 (0.79) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL697430 | 0.79 | MAP2K1 (0.71) | MAP2K1MAP2K2 | |
| SCHEMBL13148419 | 0.79 | MAP2K1 (0.56) | MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | claimed |
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NRAS, BRAF, MAP3K1 | MAP2K1 48/4885MAP2K2 38/4885MAP2K5 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.